The Impella RP is the only percutaneous heart pump approved for right heart support:
- Provides right ventricular unloading: Actively delivers 4.0+ L/min of continuous flow to the pulmonary artery*
- Indicated for use for up to 14 days
- Enables biventricular support**

**As demonstrated in the RECOVER RIGHT clinical trial
**When used in conjunction with a durable LVAD system or if Impella has already been placed for left heart support.

---

### Who is the Intended User?

- Impella RP is for physicians who need to unload the right ventricle with continuous hemodynamic support.

### Who is the Patient?

- Post Cardiac Surgery
- Post Heart Transplant
- Post-AMI Cardiogenic Shock
- Post-LVAD

### Surgical Accessories

- 23 Fr x 6 cm Peel-away introducer with hemostatic valve
- 8 - 20 Fr Sequential dialators
- 0.027” x 260cm Guidewire
- 0.035” x 150cm Stiff guidewire

---

**Product Overview**

- Inserted through the femoral vein
- Integrated microaxial impeller pulls blood from the inferior vena cava to the pulmonary artery
- Uses a differential pressure sensor
  - An electronic sensor that measures the pressure difference between the inside and outside of the cannula
  - Flexible membrane integrated into the cannula
  - Generates the placement signal used to monitor position and calculate flow
- Weaning protocol to determine RV contractility
Impella RP® Heart Pump

- The Impella RP post-approval study data compares to a survival rate of 73% in the Impella RP PMA Study, 43%.
- The Impella RP FDA post-market study data shows 64% survival rate for patients who meet the Recover Right criteria.
- Abiomed encourages clinicians to review proper inclusion and exclusion criteria for Impella RP and to follow best practices guidelines.

**Indications for Use**

The Impella RP® System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area ≥1.5 m² who develop acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery.

**Important Risk Information for Impella devices**

**Contraindications**

The Impella RP System is contraindicated for patients with the following conditions: Disorders of the pulmonary artery wall that would preclude placement or correct positioning of the Impella RP device; Mechanical valves, severe valvular stenosis or valvular regurgitation of the tricuspid or pulmonary valve; Mural thrombus of the right atrium or vena cava; Anatomic conditions precluding insertion of the pump; Presence of a vena cava filter or caval interruption device, unless there is clear access from the femoral vein to the right atrium that is large enough to accommodate a 22 Fr catheter.

*This condition is a contraindication for the cardiogenic shock indication only.*

**Potential Adverse Events**

The potential adverse effects (eg, complications) associated with the use of the Impella RP System: Arrhythmia, Atrial fibrillation, Bleeding, Cardiac tamponade, Cardiogenic shock, Death, Device malfunction, Hemolysis, Hepatic failure, Insertion site infection, Perforation, Pulmonary embolism, Pulmonary valve insufficiency, Respiratory dysfunction, Septic, Thromboembolism, Thrombotic vascular (non-central nervous system) complication, Tricuspid valve injury, Vascular injury, Venous thrombosis, Ventricular fibrillation and/or tachycardia.

In addition to the risks above, there are other **Warnings** and **Precautions** associated with Impella devices. To learn more, visit: [www.abiomed.com/important-safety-information](http://www.abiomed.com/important-safety-information)